Evaluation of HS-20137 in Chinese Patients with Moderate-to-Severe Psoriasis: Results from a Phase 2, Randomized, Double-Blind Trial - Takeaways - MDSpire

Evaluation of HS-20137 in Chinese Patients with Moderate-to-Severe Psoriasis: Results from a Phase 2, Randomized, Double-Blind Trial

  • By

  • Lin Cai

  • Xiaohua Wang

  • Litao Zhang

  • Guoqiang Zhang

  • Liming Wu

  • Baoqi Yang

  • Zudong Meng

  • Jihai Shi

  • Guangming Han

  • Aihua Wei

  • Shanshan Li

  • Yi Zhao

  • Juan Su

  • Nianjin Wei

  • Siying Liu

  • Ran Liu

  • Wei Liu

  • Min Fang

  • Xiaoqing Zhang

  • Jianzhong Zhang

  • March 22, 2026

  • 0 min

Share

  • 1

    HS-20137 is a novel IL-23p19 monoclonal antibody evaluated for safety and efficacy in Chinese patients with moderate-to-severe psoriasis.

  • 2

    The phase 2 trial demonstrated significant improvement in psoriatic lesions and quality of life over 52 weeks.

  • 3

    HS-20137 showed an excellent long-term therapeutic effect and safety profile, comparable to other IL-23 antibodies.

  • 4

    The study supports further development of HS-20137 as a competitive treatment option for psoriasis.

  • 5

    Eligible participants included adults aged 18–75 with moderate-to-severe plaque psoriasis, assessed by specific severity scores.

Original Source(s)

Evaluation of HS-20137 in Chinese Patients with Moderate-to-Severe Psoriasis: Results from a Phase 2, Randomized, Double-Blind Trial

  • by Lin Cai, Xiaohua Wang, Litao Zhang, Guoqiang Zhang, Liming Wu, Baoqi Yang, Zudong Meng, Jihai Shi, Guangming Han, Aihua Wei, Shanshan Li, Yi Zhao, Juan Su, Nianjin Wei, Siying Liu, Ran Liu, Wei Liu, Min Fang, Xiaoqing Zhang, Jianzhong Zhang

  • March 22, 2026

Related Content

Survey on Real-World Interventions and Strategies for Treat-to-Target Approaches in Psoriasis Management in Canada

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

Navigating renal safety in the biologic treatment of psoriasis: from immunologic mechanisms to clinical practice